This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2002 Oct 7;196(7):873-5.

doi: 10.1084/jem.20021404.

Alpha E: no more rejection?

Peter J Kilshaw¹, Jonathan M G Higgins

Affiliations

PMID: 12370249
PMCID: PMC2194032
DOI: 10.1084/jem.20021404

Review

Alpha E: no more rejection?

Peter J Kilshaw et al. J Exp Med. 2002.

. 2002 Oct 7;196(7):873-5.

doi: 10.1084/jem.20021404.

Authors

Peter J Kilshaw¹, Jonathan M G Higgins

Affiliation

¹ The Babraham Institute, Cambridge, CB2 4AT, United Kingdom. peter.kilshaw@bbsrc.ac.uk

PMID: 12370249
PMCID: PMC2194032
DOI: 10.1084/jem.20021404

No abstract available

PubMed Disclaimer

Comment on

CD103 expression is required for destruction of pancreatic islet allografts by CD8(+) T cells.
Feng Y, Wang D, Yuan R, Parker CM, Farber DL, Hadley GA. Feng Y, et al. J Exp Med. 2002 Oct 7;196(7):877-86. doi: 10.1084/jem.20020178. J Exp Med. 2002. PMID: 12370250 Free PMC article.

Similar articles

CD103 expression is required for destruction of pancreatic islet allografts by CD8(+) T cells.
Feng Y, Wang D, Yuan R, Parker CM, Farber DL, Hadley GA. Feng Y, et al. J Exp Med. 2002 Oct 7;196(7):877-86. doi: 10.1084/jem.20020178. J Exp Med. 2002. PMID: 12370250 Free PMC article.
Renal allograft rejection: the contribution of chemokines to the adhesion and retention of alphaE(CD103)beta7 integrin-expressing intratubular T cells.
Al-Hamidi A, Pekalski M, Robertson H, Ali S, Kirby JA. Al-Hamidi A, et al. Mol Immunol. 2008 Sep;45(15):4000-7. doi: 10.1016/j.molimm.2008.06.011. Epub 2008 Jul 22. Mol Immunol. 2008. PMID: 18649941
Different roles for alpha 4-integrin/VCAM-1 and alpha 4/fibronectin interactions in allograft rejection.
Stegall MD, Elices M, Pietra W, Shepard G, Gup C, Gill RG. Stegall MD, et al. Transplant Proc. 1999 Feb-Mar;31(1-2):786. doi: 10.1016/s0041-1345(98)01767-9. Transplant Proc. 1999. PMID: 10083336 No abstract available.
Approaches to the prevention of immune destruction of transplanted pancreatic islets.
Lafferty KJ, Hao L. Lafferty KJ, et al. Transplant Proc. 1994 Apr;26(2):399-400. Transplant Proc. 1994. PMID: 8171476 Review. No abstract available.
Immunosuppressive drugs for kidney transplantation.
Halloran PF. Halloran PF. N Engl J Med. 2004 Dec 23;351(26):2715-29. doi: 10.1056/NEJMra033540. N Engl J Med. 2004. PMID: 15616206 Review. No abstract available.

See all similar articles

Cited by

Animal models have little to teach us about type 1 diabetes: 2. In opposition to this proposal.
Leiter EH, von Herrath M. Leiter EH, et al. Diabetologia. 2004 Oct;47(10):1657-60. doi: 10.1007/s00125-004-1518-0. Epub 2004 Oct 19. Diabetologia. 2004. PMID: 15502929 Review. No abstract available.
IL-7 uniquely maintains FoxP3(+) adaptive Treg cells that reverse diabetes in NOD mice via integrin-β7-dependent localization.
Li CR, Deiro MF, Godebu E, Bradley LM. Li CR, et al. J Autoimmun. 2011 Nov;37(3):217-27. doi: 10.1016/j.jaut.2011.06.002. Epub 2011 Jul 13. J Autoimmun. 2011. PMID: 21745722 Free PMC article.
Infection of CD127+ (interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection.
Zaunders JJ, Ip S, Munier ML, Kaufmann DE, Suzuki K, Brereton C, Sasson SC, Seddiki N, Koelsch K, Landay A, Grey P, Finlayson R, Kaldor J, Rosenberg ES, Walker BD, Fazekas de St Groth B, Cooper DA, Kelleher AD. Zaunders JJ, et al. J Virol. 2006 Oct;80(20):10162-72. doi: 10.1128/JVI.00249-06. J Virol. 2006. PMID: 17005693 Free PMC article.
TGF-β enhances the cytotoxic activity of Vδ2 T cells.
Peters C, Meyer A, Kouakanou L, Feder J, Schricker T, Lettau M, Janssen O, Wesch D, Kabelitz D. Peters C, et al. Oncoimmunology. 2018 Sep 26;8(1):e1522471. doi: 10.1080/2162402X.2018.1522471. eCollection 2019. Oncoimmunology. 2018. PMID: 30546961 Free PMC article.
Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes.
Li CR, Baaten BJ, Bradley LM. Li CR, et al. J Mol Cell Biol. 2012 Feb;4(1):38-47. doi: 10.1093/jmcb/mjr040. Epub 2011 Nov 24. J Mol Cell Biol. 2012. PMID: 22116888 Free PMC article. Review.

See all "Cited by" articles

References

1. Kilshaw, P.J. and J.M.G. Higgins. 2002. Integrin αEβ7: molecular features and functional significance in the immune system. I-Domains in Integrins. D. Gullberg, editor. Landes Bioscience, Georgetown, TXIn press.
1. Lehmann, J., J. Huehn, M. de la Rosa, F. Maszyna, U. Kretschmer, V. Krenn, M. Brunner, A. Scheffold, and A. Hamann. 2002. Expression of the integrin αEβ7 identifies unique subsets of CD25+ as well as CD25− regulatory T cells. Proc. Natl. Acad. Sci. USA. In press. - PMC - PubMed
1. Roberts, K., and P.J. Kilshaw. 1993. The mucosal T cell integrin αM290β7 recognises a ligand on mucosal epithelial cells. Eur. J. Immunol. 23:1630–1635. - PubMed
1. Schön, M.P., A. Arya, E.A. Murphy, C.M. Adams, U.G. Strauch, W.W. Agace, J. Marsal, J.P. Donohue, H. Her, D.R. Beier, et al. 1999. Mucosal T lymphocytes are selectively reduced in integrin αE (CD103)-deficient mice. J. Immunol. 162:6641–6649. - PubMed
1. Schön, M.P., M. Schön, H.B. Warren, J.P. Donohue, and C.M. Parker. 2000. Cutaneous inflammatory disorder in integrin αE (CD103)-deficient mice. J. Immunol. 165:6583–6589. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Molecular Biology Databases
- BioCyc